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RESUMO 
 
Introdução: A diabetes tem sido associada a mau prognóstico cardiovascular. No 
entanto, escassos estudos têm sido desenvolvidos em pacientes pós enfarte agudo do 
miocárdio que evoluem com função cardíaca preservada. O objetivo deste trabalho é 
descrever as correlações clínicas e valor prognóstico da diabetes em pacientes pós-
enfarte agudo do miocárdio (EAM) em pacientes que evoluem com fração de ejeção do 
ventrículo esquerdo preservada (FEVE).  
Métodos: Estudamos doentes referenciados para o programa de reabilitação cardíaca 
após enfarte agudo do miocárdio, entre Janeiro de 2010 e Dezembro de 2012. Estes 
tinham de ter fração de ejeção do ventrículo esquerdo >=50% à data da alta (medida 
por ecocardiografia transtorácica) e completado o programa de reabilitação cardíaca. 
Os dados laboratoriais foram colhidos a partir de medição de análises sanguíneas 
durante o internamento. O outcome composto foi definido como morte de qualquer 
causa, hospitalização por insuficiência cardíaca, diagnóstico de novo ou agravamento 
da insuficiência cardíaca no doente seguido em ambulatório. 
Resultados: Os 336 doentes estudados tinham uma média de idades de 60 ±11 anos 
e 76% eram do sexo masculino. 31% eram diabéticos e 75% tinham dislipidémia, 
hipertensão (61%) e história passada ou presente de tabagismo (63%) foram fatores de 
risco cardiovascular prevalentes. A diabetes estava associada com idade mais 
avançada (63 anos ± 10 vs 58 ± 11), sexo feminino (34% vs 19%, p=0.002), um maior 
índice de massa corporal (28 ± 4 vs 26 ± 4, p<0.001) e história de hipertensão (80% vs 
53%, p<0.001). Estes pacientes tiveram também classificações de Killip mais altas 
(Classe de Killip II 18% vs 6%, p=0.001).  
Conclusão: Em pacientes pós enfarte agudo do miocárdio com fração de ejeção do 
ventrículo esquerdo preservada, a diabetes está associada a pacientes mais frágeis, 
doença arterial coronária mais severa e incidência mais alta de insuficiência cardíaca 
durante a hospitalização. Diabetes foi a única característica clínica capaz de predizer o 
prognóstico neste grupo heterogéneo de pacientes. 
 
Termos MeSH: Enfarte do Miocárdio, Disfunção Ventricular, Esquerda; Diabetes 
Mellitus ; Insuficiência Cardíaca 
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ABSTRACT 
 
Introduction: Diabetes has long been associated with adverse cardiovascular 
outcomes. Scarce data is available on the clinical significance of this prevalent 
comorbidity in post-acute myocardial infarction (AMI) patients who evolve with preserved 
cardiac function. We aimed to describe the clinical correlates and prognostic value of 
diabetic status in post-AMI patients evolving with preserved Left Ventricular Ejection 
Fraction. 
Methods: We studied patients referred to a cardiac rehabilitation (CR) program after an 
acute myocardial infarction (AMI) between January 2010 and December 2012. They had 
to have a Left Ventricle Ejection Fraction >=50% at the time of hospital discharge 
(measured by transthoracic echocardiography) and completed cardiac rehabilitation 
program. The laboratorial data was collected from blood analysis measurement during 
hospitalization. The composite outcome was defined as all-cause death, heart failure 
hospitalization, de novo diagnosis or worsening HF at the outpatient clinic, and it was 
assessed by chart review. 
Results: The 336 studied patients had a mean age of 60 ±11 years and 76% were male. 
31% were diabetic and 75% had dyslipidemia, hypertension (61%) and present or past 
smoking (63%) were prevalent cardiovascular risk factors. Diabetic status was 
associated with older age (63y ± 10 vs 58 ± 11), female gender (34% vs 19%, p=0.002), 
higher body mass index (28 ± 4 vs 26 ± 4, p<0.001) and a history of hypertension (80% 
vs 53%, p<0.001). They also evolved with higher Killip classes (Killip class II 18% vs 
6%, p=0.001).  
Conclusion: In post-acute myocardial infarction patients with preserved left ventricle 
ejection fraction, diabetic status is associated with more fragile patients, severe coronary 
artery disease and higher incidence of heart failure during hospitalization. Diabetes was 
the only clinical feature to predict outcome in this heterogeneous group of patients. 
 
MeSH terms: Myocardial Infarction; Ventricular Dysfunction, Left ; Diabetes Mellitus ; 
Heart Failure 
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INTRODUCTION 
Diabetes is one of the most prevalent chronic diseases worldwide and has a 
growing incidence [1-3]. Diabetics have a heightened risk of developing cardiovascular 
disease (CVD) [4-7], and among those with established CVD it is associated with worse 
prognosis. Approximately 40% to 50% of patients with coronary heart disease (CHD) 
have type 2 diabetes [8]. In this subset of patients, it increases the risk of having an acute 
coronary syndrome and the risk of dying [9-11]. In heart failure with reduced ejection 
fraction, diabetes increases the risk of cardiovascular mortality, hospitalization and 
sudden death. In heart failure with preserved ejection fraction (HFpEF), diabetics might 
represent a distinct phenotype characterized by specific functional and prognostic 
features [12]. New drugs recently approved for treatment of diabetes [13-15] impressively 
reduced cardiovascular death and heart hospitalizations, opening new windows of 
opportunity to minimize cardiovascular outcomes in diabetics.  
Advances in pharmacological and mechanical reperfusion of acute myocardial 
infarction (AMI) over the past decades led to a significant improvement in survival and to 
an increasing proportion of post-AMI patients evolving with preserved left ventricle 
ejection fraction LVEF[16]. These patients have a better prognosis than those with 
reduced LVEF [17], however their clinical course is not as benign as previously 
presumed [17, 18]. Sudden cardiac death (SCD) incidence in this subgroup represent 
the greatest absolute number of SCD in the post-AMI setting [19]. Atrial fibrillation (AF) 
– an important prognostic marker in cardiovascular disease patients – complicates the 
clinical course of up to 58% of patients with preserved LVEF during the 2 years following 
an AMI [20]. Scarce data is available about the prognostic value of diabetic status in 
post-AMI patients evolving with preserved LVEF.  
In this study, we aimed to describe the clinical correlates and prognostic value of 
diabetic status in post-AMI patients with preserved LVEF. 
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METHODS 
We studied 336 consecutive patients that completed a cardiac rehabilitation 
program after an acute myocardial infarction (AMI) between January 2010 and 
December 2012 at Centro Hospitalar do Porto (Porto, Portugal).  
We excluded patients with LVEF < 50% at the time of discharge. 
Clinical, laboratorial, and echocardiographic data were collected by chart review. Supine 
transthoracic echocardiography was performed in all patients before the hospital 
discharge. LVEF was either calculated using the biplane Simpson method or eyeballing.  
Dimensions and volumes of cardiac chambers and left ventricular mass were measured 
according to current international recommendations [21]. The laboratorial data was 
collected from blood analysis measurement during hospitalization. NT-proBNP was 
measured using the Roche® NT-proBNP assay. Anemia was defined as hemoglobin 
less than 12 g/dL for women and less than 13 g/dL for men. Chronic kidney disease 
(CKD) was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/ 1.73 
m2. 
Incident outcome events were defined as the first occurrence of all-cause death, 
heart failure hospitalization, or AMI. All events were collected by chart review. 
This study conforms with the principles outlined in the Declaration of Helsinki and was 
approved by the institution's ethical committee (N/REF.ª 2016.236/199-DEFI/188-CES). 
 
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation for normally 
distributed data or median [25th, 75th percentiles] for non-normally distributed data. 
Categorical variables are expressed as number of subjects and proportion [n (%)]. 
Comparisons between groups were performed using 2-sided unpaired or paired t tests 
or Wilcoxon rank sums test for normally and non-normally distributed data, respectively. 
Fisher’s exact test was applied to compare proportions. One-way ANOVA with 
Bonferroni correction was used to perform multiple group comparisons. Correlations 
between hemodynamic and metabolic variables were determined using Pearson or 
Spearman correlation for normally and non-normally distributed data, respectively. We 
used univariate and multivariable Cox proportional hazards regression models to study 
the relationship between diabetes and the composite outcome. Statistical analysis was 
performed using Stata software Version 12.1 (Stata Corp LP, College Station, TX, USA). 
A two-sided p-value <0.05 was considered significant. 
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RESULTS 
Studied population 
Clinical and demographic characteristics of the studied population are 
summarized in Table I. Of the 336 studied patients, 99 (31%) were diabetic. Most 
patients were male (76%) and had a mean age of 59±11 years. Dyslipidemia (75%), 
hypertension (61%), present or past smoking (63%) and diabetes (29%) were the most 
common cardiovascular risk factors. Eighteen per cent had previously been diagnosed 
with CAD. Clinical presentation with an ST-segment elevation myocardial infarction 
(STEMI) represented 44% of the overall patients. Three-vessel CAD was seen in a third 
of the patients. Left anterior descendent was the culprit vessel in 41% of the patients and 
percutaneous coronary intervention (PCI) was performed in 88% of them. The median 
and interquartile range of peak values of troponin and creatinine-kinase (CK) were 2.63 
ng/mL and 900 U/L, respectively. The echocardiographic characteristics of the overall 
patients are displayed in Table II. During the index hospitalization, almost 8% of patients 
showed signs and symptoms of heart failure (6% in Killip class II and 2% in class III). At 
the time of discharge, more than 96% of the patients were medicated with dual 
antiplatelet therapy and statins. Medication at discharge is displayed in Table I. 
 
Clinical and echocardiographic correlates of diabetes 
Diabetic status was associated with older age (63y ± 10 vs 58y ± 11, p< 0.001), 
female gender (34% vs 19%, p=0.002), higher body mass index (28±4 vs 26±4, p< 0.001) 
and a history of hypertension (80% vs 53%, p<0.001). Diabetic patients were more likely 
to present with a non-ST segment elevation myocardial infarction (65% vs 52%, 
p=0.035), and they had significantly lower troponin T (0.4 [0.0-1.6] vs 1.2 [0.2–3.2] 
ng/mL, p< 0.001) and creatine kinase peak concentration (251 [91-840] vs 456 [161-
1436] U/L, p=0.002) when compared to non-diabetic patients. They evolved with higher 
Killip classes (Killip class II 18% vs 6%, p=0.001) and were more likely to need diuretic 
treatment at hospital discharge (12% vs 4%, p=0.005).  
No significant differences between groups were observed regarding cardiac 
phenotype assessed by echocardiography (volumes and dimensions, segmental motion 
abnormalities and left ventricular remodeling pattern) at hospital discharge. 
 
Prognostic value of diabetes 
  Over a follow-up of 3.7±1.8 years, composite outcome occurred in 24 (7%) 
patients (14 deaths, 4 HF hospitalizations and 6 acute coronary syndromes). The overall 
incident rate was 2.0 events per 100 000 person-years. Diabetics had an almost 4-fold 
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risk of having an adverse event during the follow-up (HR 3.75; 95%CI 1.64-8.57; 
p=0.002). After adjusted for age and sex, diabetes remained an independent risk factor 
(HR 3.44; 95%CI 1.46-8.09; p= 0.005). 
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DISCUSSION 
 In the studied post-AMI with preserved LVEF patients, a third were diabetic. 
These were older, more likely to be female and had increased BMI and dyslipidemia 
prevalence. Despite more severe CAD, diabetics were more likely to have a NSTEMI, 
had reduced myocardial infarction size as assessed by peak troponin but higher 
incidence of heart failure during hospitalization. Diabetes independently predicted 
prognosis, signalling a 3-fold increase risk of composite outcome. 
 The results showed that the incidence of type 2 diabetes is significantly higher in 
individuals aged >60 years and female gender is the most affected by this disease. This 
data were concordant with the last edition of IDF Diabetes Atlas[1]. Cardiovascular risk 
factors were also more often seen in this patients, such as high BMI, hypertension and 
dyslipidemia[22]. The characteristics of our study population are similar with the previous 
studies with patients with cardiovascular disease[23-26].  
Atherosclerosis is the major disease process of CAD[27]. Dyslipidemia has an 
important role in pathogenesis of atherosclerosis[28]. So, attending to the highly 
correlation between diabetes and dyslipidemia[29] and to chronic inflammation present 
in diabetes[30-36] it culminates in a high risk of cardiovascular events. Which agrees 
with other data which shows CAD as the most common cause of death in patients with 
type 2 diabetes with almost 70% of cases[37]. 
 Our data indicate that diabetics had higher Killip class during hospitalization 
which means worst prognosis. Available data about hospitalization in diabetics shows 
higher length of stay in this patients comparing with patients without diabetes[38, 39]. 
However there aren’t studies using the Killip classification.  
 Besides diabetes, this patients tend to be older and have more cardiovascular 
risk factors such as dyslipidemia or hypertension as shows our study, which confers to 
these patients a more fragile status. By itself this could justify a worst prognosis in these 
patients however diabetes can lead to a cardiac contractile dysfunction not related with 
coronary artery disease but consequence of mitochondrial deterioration[40-42]. A recent 
study showed that diabetic rats exhibited ventricular systolic and diastolic dysfunction 
when hearts were exposed to overload comparing to controls[43] so we may be facing a 
new cardiac phenotype dysfunction. 
 Diabetes is nowadays a major public health problem, affecting millions of people 
worldwide and being currently the most costly disease in the US health care system[44]. 
In the AMI setting, patients with diabetes have higher mortality rates during the acute 
phase and in the long term[45]. Moreover, CVD is the most common cause of morbidity 
and mortality among the diabetic population[46]  
6 
 
 Therefore, diabetic patients might benefit from more aggressive treatment of 
CAD, particularly those with multivessel coronary disease[47-49] and intensive 
intervention on risk factors. 
Recently, new antidiabetic drugs such as SGLT-2 inhibitors have demonstrated 
beneficial effects on cardiovascular risk among patients with diabetes mellitus. 
 The improvement in cardiovascular (CV) outcomes was first observed in the 
Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients 
(EMPA-REG OUTCOME) study which demonstrated that the addition of empagliflozin to 
the antidiabetes treatment reduces CV mortality by 38% in type 2 diabetes mellitus 
patients with high CV risk[50]. Later, Canagliflozin was shown to reduce the composite 
endpoint of CV mortality, nonfatal myocardial infarction (MI), or nonfatal stroke in 
14%[51]. Recently, the class effect of SGLT2 inhibitors on CV events reduction was also 
confirmed in new analyses of the The Comparative Effectiveness of Cardiovascular 
Outcomes (CVD-REAL) study with real world data from more 300,000 patients with 
T2DM across 6 countries[52]. 
 Our study has several limitations that should be considered. The study has a 
retrospective design with a relatively small cohort size from a single centre. These 
features limit the statistical power and the generalizability of our findings. Also, the most 
fragile patients with more comorbidities are less likely to complete cardiac rehabilitation 
program. Therefore, using this approach we did not studied a representative sample of 
AMI patients and increased the risk of selection bias.  
 
 
CONCLUSION 
In post-AMI patients with preserved LVEF, diabetic status is associated with more 
fragile patients, severe CAD and higher incidence of HF during hospitalization. Diabetes 
was the only clinical feature to predict outcome in this heterogeneous group of patients. 
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TABLES 
Table I – Clinical characteristics of studied patients. 
Characteristic Overall 
(n=336) 
Non-diabetic 
patients 
(n=227) 
Diabetic 
patients  
(n=99) 
P-value 
Age, y 59.50 ± 10.97 58.16 ± 11.20 62.52 ± 9.86 < 0.001 
Male, n (%) 253 (76%) 184 (81%) 65 (66%) 0.002 
BMI, Kg/m2 26.56± 3.88 25.98 ± 3.85 27.82 ± 3.59 < 0.001 
Hypertension, n (%) 201 (61%) 120 (53%) 79 (80%) < 0.001 
Smoking status 
   Never smoked, n (%) 
   Past smoker, n (%) 
   Current smoker, n (%) 
 
122 (37%) 
81 (25%) 
 124 (38%) 
 
75 (33%) 
54 (24%) 
97 (43%) 
 
46 (47%) 
27 (27%) 
26 (26%) 
0.23 
Dyslipidemia, n (%) 245 (75%) 163 (72%) 80 (82%) 0.07 
History of atrial 
fibrillation, n (%) 
5 (2%) 1 (2%) 3 (8%) 0.11 
History of heart failure, n 
(%) 
3 (1%) 3 (1%) 2 (2%) 0.64 
Stroke, n (%) 10 (3%) 6 (3%) 4 (4%) 0.51 
CAD, n (%) 59 (18%) 40 (18%) 17 (17%) 0.91 
COPD, n (%) 12 (4%) 6 (3%) 6 (6%) 0.13 
OSA, n (%) 4 (1%) 3 (1%) 1 (1%) 0.81 
ACS hospitalization 
features 
    
STEMI, n (%) 143 (44%) 108 (48%) 34 (35%) 0.035 
Killip class 
    II, n (%) 
    III, n (%) 
    IV, n (%) 
 
16 (6%) 
5 (2%) 
3 (1%) 
 
8 (4%) 
1 (1%) 
1 (1%) 
 
8 (10%) 
4 (5%) 
2 (3%) 
0.001 
Number of coronaries with 
significant disease 
   One-vessel, n (%) 
 
 
113 (36%) 
 
 
83 (38%) 
 
 
29 (30%) 
0.047 
vi 
 
   Two-vessel, n (%) 
   Three-vessel, n (%) 
99 (31%) 
105 (33%) 
70 (32%) 
65 (30%) 
27 (28%) 
40 (42%) 
Culprit coronary  
127 (41%) 
114 (37%) 
70 (22%) 
 
84 (39%) 
79 (36%) 
53 (24%) 
 
41 (45%) 
35 (38%) 
16 (17%) 
0.74 
   LAD, n (%) 
   RCA, n (%) 
   LCx, n (%) 
PCI, n (%) 286 (88%) 196 (88%) 87 (89%) 0.84 
Atrial fibrillation, n (%)  12 (4%) 8 (4%) 3 (3%) 0.82 
Blood analysis at 
discharge 
    
GFR, mL/min/1.73 m2 85.41 ± 18.56 86.19 ± 17.67 83.99 ± 20.29 0.34 
GFR < 60 mL/min/1.73 
m2, n (%) 
32 (10%) 19 (8%) 12 (12%) 0.30 
Hb, g/dL 13.44 ± 1.44 13.50 ± 1.33 13.33 ± 1.67 0.35 
Anemia, n (%) 58 (25%) 54 (24%) 24 (24%) 0.95 
Peak CK, U/L 899.88 ± 
1179.72 
456 [161-
1436] 
251 [91-840] 0.002 
Peak TnT, ng/mL 2.63 ± 4.55 1.2 [0.2 – 3.2] 0.4 [0.0-1.6] < 0.001 
NT-Pro-BNP, ng/mL 823.22  407 [176-823] 382 [177-1021] 0.99 
HbA1c (%) 6.13 ± 1.36 5.53 ± 0.50 7.42 ± 1.69 < 0.001 
Medication at discharge     
Aspirin, n (%) 323 (99%) 222 (99%) 97 (100%) 0.25 
Clopidogrel/Ticagrelor, n 
(%) 
 316 (97%) 217 (96%) 95 (98%) 0.48 
Statin, n (%) 312 (96%) 215 (96%) 93 (96%) 0.90 
B-Blocker, n (%) 297 (91%) 203 (90%) 90 (93%) 0.46 
ACEI/ARB, n (%) 233 (72%) 155 (70%) 74 (76%) 0.22 
Diuretic, n (%) 21 (7%) 9 (4%) 12 (12%) 0.005 
MRA, n (%) 6 (2%) 3 (1%) 3 (3%) 0.29 
Caption: BMI, Body Mass Index; HF, Heart Failure; CAD, Coronary Artery Disease; 
COPD, Chronic Obstructive Pulmonary Disease; OSA, Obstructive Sleep Apnea; ACS, 
Acute Coronary Syndrome; STEMI, ST Segment Elevation Myocardial Infarction; 
LAD, Left Anterior Descending Artery; RCA, Right Coronary Artery; LCx, Left 
vii 
 
Circumflex Artery; PCI, Percutaneous Coronary Intervention; GFR, Glomerular 
Filtration Rate; Hb, Hemoglobin; CK, Creatine Kinase; TnT, Troponine T; Pro-BNP, 
Pro-B-type natriuretic peptide; ACEI/ARB, Angiotensin-converting-enzyme 
Inhibitor/Angiotensin II Receptor Blocker; MRA, Mineralocorticoid Receptor 
Antagonist. 
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Table II – Echocardiographic features of studied patients. 
Characteristic Overall 
(n=336) 
Non-diabetic 
patients 
(n=227) 
Diabetic 
patients 
(n=99) 
P-value 
LV mass 
indexed, g/m2  
103.4 ± 23.0 103.11 ± 23.0 103.61 ± 23.2 0.87 
LVEDD, mm 46.20 ± 4.77 46.42 ± 4.71 45.64 ± 4.92 0.21 
LVESD, mm 30.00 ± 5.01 30.22 ± 5.40 29.47 ± 3.85 0.33 
LA diameter, 
mm 
38.66 ± 4.64 38.34 ± 4.90 39.39 ± 3.87 0.08 
LA area, cm2 20.12 ± 3.97 19.98 ± 4.18 20.42 ± 3.44 0.40 
LA volume, 
cm2 
59.59 ± 15.66 59.32 ± 17.71 60.06 ± 11.74 0.88 
Segmental 
motion 
abnormalities 
 
Anterior, n (%)  89 (28%) 67 (30%) 20 (21.7%) 0.12 
Posterior, n (%) 141 (45%) 99 (45%) 41 (45%) 1.00 
Inferior, n (%) 178 (57%) 125 (57%) 52 (57%) 0.99 
Moderate/severe 
MR, n (%) 
11 (4%) 8 (4%) 3 (3%) 0.86 
PSAP  25.82 ± 5.62 25.46 ± 5.43 26.70 ± 6.08 0.21 
RV systolic 
dysfunction, n 
(%) 
8 (3%) 6 (3%) 2 (2%) 0.78 
LV 
remodelling 
pattern 
 
   Normal, n (%) 76 (23%) 61 (27%) 15 (15%)  
   Concentric, n 
(%) 
123 (37%) 82 (36%) 41 (41%) 
ix 
 
   Concentric 
LVH, n (%) 
109 (33%) 66 (29%) 36 (36%) 0.08 
   Eccentric 
LVH, n (%) 
24 (7%) 17 (8%) 7 (7%) 
Caption: IVS, Interventricular Septum; PWT, Posterior Wall Thickness; LVEDD, Left 
Ventricular End Diastolic Diameter; LVESD, Left Ventricular End Sistolic Diameter; 
LA, Left Auricle; MR, Mitral Regurgitation; LV, Left Ventricle; LVH, Left Ventricular 
Hypertrophy. 
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Table III – Association of diabetic status and composite outcome. 
 
  Non-diabetic Diabetic Dichotomous 
  N Events 
Event Rate/100 
person years 
(95% CI) 
N Events 
Event Rate/100 
person 
years(95% CI) 
HR (95% CI) 
P-
value 
Unadjus
ted 
2559 199 2.30(2.00-2.65) 595 84 4.40(3.56-5.46) 1.91 (1.48-2.47) <0.001 
Adjuste
d for age 
and sex 
      1.68 (1.30-2.18) <0.001 
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FIGURE 1 – Survival curves according to diabetic status (p=0.002). 
 
 
 
